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Background: Breast metastasis is fairly uncommon and prognosis is dismal. Breast metastasis might be the first
symptom or may occur during the course of other malignancies dominantly arising from the contralateral breast.
Leukemia, lung cancer and conjunctival melanoma may spread to the breast.
Case presentation: A 43-year-old female patient was operated on for conjunctival melanoma. After two years the
disease progressed quickly and cutaneous nodes appeared on the back and paraumbilical region. Physical and
radiological examination showed a breast mass. No palpable lymph’s nodes were noted. She underwent an open
biopsy. Histopathologic examination and immunohistochemistry confirmed breast metastases from melanoma.
During post-operative staging multiple nasopharyngeal and oropharyngeal lesions were also objective. The patient
was given palliative dacarbazine (250 mg/m2 per day for 4 days) for 4 cycles. She died 4 months after the diagnosis
of breast metastases.
Conclusion: Histopathological evaluation should be mandatory in patients with medical history of malignancies
in order to differentiate new primary tumors, metastases, and benign tumors.
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Melanoma of the conjunctiva is a relatively rare and highly
aggressive ocular malignancy [1]. These tumors’ may in-
vade the orbit and the eye and metastasize to regional
lymph nodes and systemically [2]. Breast metastases from
extra mammary cancers are rare and melanoma is one of
the malignancies that can metastasize to the breast. Benign
and primary malignant breast tumors are quite common,
but secondary tumors in the breast from metastatic malig-
nancies are rare. Here we report a case of a young woman
diagnosed with breast metastases from a conjunctival
melanoma.Case presentation
A 43-year-old female with no personal or familial patho-
logical disease previously, and negative history of systemic* Correspondence: saoussane.oncomed@gmail.com
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article, unless otherwise stated.disease treated by enucleation two years ago for primary
conjunctival melanoma (Figures 1 and 2), without adju-
vant radiotherapy. During regular follow-up visits no
residual or recurrent lesion occurred. Two years after,
she presented multiples cutaneous lesions. Physical
examination demonstrates multiple cutaneous nodules
on the back and paraumbilical region. Breast examination
revealed a 2 cm hard lump in the left breast, and no palp-
able lymph nodes. Physical examination of the contra-
lateral breast was normal. Mammography and ultrasound
showed a lobulated contoured left breast mass reported as
BI-RADS 4 (Breast Imaging-Reporting and Data System).
An open biopsy was performed. Morphological examin-
ation showed a solid tumor suggesting a melanoma involve-
ment (Figures 3 and 4). Immunoassaying was performed
showing a negative staining for cytokeratin markers and
hormonal receptors. However it showed strong positivitytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0) which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Low power view showing a diffuse tumoral proliferation
of round cells (Hematoxylin and eosin × 10).
Figure 3 Histologic section show a breast parenchyma infiltrated
by melanocytic prolifération (hematoxylin and eosin × 10).
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ing for Melan-A and HMB-45 (Human Melanoma Black)
(Figure 5). These findings concluded a diagnosis of
breast metastatic disease from melanoma, and elimin-
ate malignant or benign primary breast tumor. During
post-operative staging with a whole body computed
tomography (CT) Scan, multiple nasopharyngeal and
the oropharyngeal metastases were also noted. Histo-
pathological examination of these lesions confirmed
features of metastatic disseminated disease from melan-
oma. She was given palliative dacarbazine (250 mg/m2
per day for 4 days). The patient received 4 cycles. She
died 4 months later.
Discussion
Invasive conjunctival melanoma accounts for only 1–2%
of all ocular melanomas [1]. Similar to cutaneous melano-
mas, conjunctival melanomas originate from melanocytes
that are derived from the neural crest. It is a potentially
lethal neoplasm with an average 10-year mortality rate of
30% [2]. Systemic metastases occur in 14% to 27% ofFigure 2 Higher power view showing melanoma cells some of
which are producing brown melanin pigment (Hematoxylin
and eosin × 40).cases. Breast involvement in melanoma is not an isolated
finding; it is usually associated with disseminated disease.
Subcutaneous tissue, lung, liver, and brain are common
secondary involvements in this disease [2]. Breast metasta-
sis might be the first symptom or may occur during the
course of other malignancies. Shetty et al [3], reported a
review of literature, presenting data from 1855 to 1992,
and found 431 cases of secondary extra-mammary breast
tumors. The majority of them represented metastases
from malignant melanoma (79 cases), followed by lung
cancer metastases (78 cases), ovarian cancer (50 cases),
and prostate (39 cases), kidney (24 cases), and other
(143 cases). The time between diagnosis of the primary
melanoma and the occurrence of a breast metastasis
ranged from 13 to 180 months (median 62). Clinically, a
breast lesion may mimic primary breast carcinoma. It’s
necessary to differentiate primary to secondary extra-
mammary tumors because prognosis and treatment of
these neoplasm differ. Diagnosis of breast disease involves
the work of multidisciplinary team of specialists. Radiolo-
gists perform necessary imaging for establishing optimalFigure 4 Histopathologic section show a diffuse tumoral
proliferation of round cells with large central nucleoli.
(Hematoxylin and eosin × 10).
Figure 5 Positive immunostaining of tumoral cells for HMB45
(magnification × 20).
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diagnosis. Immunocytochemical panel should be used to
confirm the diagnosis of secondary metastatic melanoma
to the breast. Our diagnosis was suspected by the
comparative examination of the primary and metastases’
histological findings, and confirmed by a complete immu-
nochemistry panel (negative staining for cytokeratin
and positive for melan A and HMB45). Breast metas-
tases are poor prognostic sign [4]. Radvel et al, re-
ported a 12.9 months median time of survival after
diagnosis of breast metastases [5]. In our case, the patient
died 4 months after starting a treatment based on
dacarbazine.
A recently published randomized controlled trial has
shown that inhibitor (BRAF and MEK) kinase improved
rates of overall and progression-free survival in patients
with previously untreated melanoma with the BRAF
V600E mutation [6].Conclusion
Metastasis to the breast must be considered in any patient
with a known primary malignant tumor history who pre-
sents with a breast lump. Histopathological evaluation
should be mandatory in patients with medical history of
malignancies in order to differentiate new primary tumors,
metastases, and benign tumors. Oncologists, surgeons,
pathologists, and radiologists have to work together to
reach the best possible therapy against this aggressive type
of cancer.Consent
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